SENNOS

Journal of Drug Delivery and Biotherapeutics (JDDB)

Journal homepage: https://sennosbiotech.com/JDDB/1

Review Article

Navigating Drug Regulatory Affairs: An Analytical Review of Compliance in the Pharmaceutical Industry

Sayali Shelke*, Vaishali Jadhav, Ashish Jain, Divya Shirsat[4], Nanduri Sri Sesha Sai Swaroop

Department of Quality Assurance, Shri D.D Vispute College of Pharmacy and Research Centre, India

ARTICLEINFO **ABSTRACT**

Drug Regulatory Affairs (DRA) plays a critical role within pharmaceutical companies, ensuring the health and safety of consumers while maintaining the integrity of pharmaceutical products. This discipline provides strategic and informed oversight to guarantee compliance with legal and regulatory requirements, expediting the development and approval of safe and effective drugs. Regulatory affairs professionals work across diverse sectors, including government agencies, the pharmaceutical industry, academia, and clinical research organizations. Their responsibilities encompass devising and implementing regulatory strategies, ensuring that drug development processes align with global standards while enhancing competitiveness in the market. The scope of DRA extends across the entire lifecycle of a pharmaceutical product, from preclinical research and development to manufacturing, marketing, and post-marketing surveillance. Additionally, the DRA department serves as the primary interface between the company and regulatory authorities, ensuring seamless communication and compliance at every stage of drug development and commercialization. Through its multifaceted role, DRA not only safeguards public health but also contributes to the efficient and successful introduction of pharmaceutical innovations.

Keywords: Pharmaceutical Inspection; Cooperation Scheme (PIC/S); FDA, Regulatory Agencies, Drug Regulatory Affairs, GMP

Corresponding Author:

Sayali Shelke

* Department of Quality Assurance, Shri D.D Vispute College of Pharmacy and Research Center, Devad, New Panvel

Email id: sayli12121212@gmail.com

Received date: 01-Sep-2024 Revised date: Sep-Jul-2024, Accepted date: 15-Oct-2024

Crossref DOI: https://doi.org/10.61920/jddb.v1i02.132

1.Introduction

Government affairs or regulatory affairs abbreviated as RA is an occupation in industries such as banking, energy, medical and health products, and pharmaceutical industries. In the context of the health care industries they are also very targeted or related to the regulatory affairs of pharmaceuticals, medical devices, biologics and functional foods. There is a widely accepted benchmark by which Regulatory Affairs specialists are usually employed in specific departments of most organizations, whether it is a small innovative biotechnology company or a multinational pharmaceutical corporation. The modern pharmaceutical industry is businesslike, orderly, and legal, it meets the international standards in manufacturing of chemical and biological preparations for human and veterinary use; medical devices, orthodox traditional herbal products, and cosmetics. Blood products and their by products are controlled under very rigid GMP while traditional herbal medicines, cosmetics, food and dietary items are prepared under controlled manner which was not the practice a century or so ago. In its present state of clear and structured regulators, the situation that each of the regulatory systems has to face is entirely correct. This has resulted in what could be termed a systemic mountain in the competitive environment of the pharmaceutical sectors. People in other parts of the globe are gradually beginning to discover that the actual struggle for existence is in managing and implementing work or activities and systematically studying and analyzing the regulations relating to those pharmaceutical activities to guarantee the efficiency and safety of such processes under regulation. Qualified and skilled personnel with the adequate experience and ability to address any arising problems or challenge affecting the regulatory department are wanted so badly. Due to its closeness to product safety the pharmaceutical industry is the most regulated of all possible industries. The field is called government affairs, or regulatory affairs (RA), and is established in industries such as biotechnology, medical technology, pharmaceuticals, and health care products. In the healthcare industry regulated by the triangulation of legislation, bureaucracy and regulation related to pharmaceuticals, nutraceuticals, medical devices, both biologic and probiotics, functional food, a regulation affair which abbreviated as RA is of a paramount significance. As one of the critical sections that are mandatory in pharma organizations, the Regulatory Affairs should be mentioned. It acts as a channel between the corporation and the authorities and as an interface between the phases of clinical, production, sales, and drug creation [2].

1.1 Complex dynamics involved in Multifaceted RA

Able to view and develop ideas from a scientific/technological standpoint; Able to articulate thoughts coherently; Capable of interacting with persons with divergent skills, experiences and cultural backgrounds; Capable of managing opposite personal and organizational objectives, loyalties, social and moral responsibilities.

Today's pharmaceutical industry is predefined, strategic, and complies with global specifications of Biological and chemical pharma products for human as well as for veterinary uses, medical instruments, cosmetics, and Ayurvedic and herbal products. Blood related products are regulated under GMP and as are the herbal medicines, cosmetics, food and dietary items which may have been prepared under controlled conditions not a century back. Each and every legal and regulatory system enables preparation and delivery of high quality and safe drugs and medication. There were many 1950 tragedies including the thalidomide, vaccination, and sulfanilamide elixir tragedies all of which caused an increase in the laws concerning efficacy, safety, and quality of a drug. This has also led to other changes such as more stringent GMPs, as well as changes in Marketing Authorization (MA). Providing that patients receive the right information regarding the medicines that they use, and the labeling of such products constitute essential tasks for the regulatory authority. Any regulatory-related activity involves the risk of millions of dollars being lost – through product recall, and a seemingly insignificant mistake occurring.

1.2 The significance of regulatory affairs

In the pharmaceutical industry regulatory affairs specialists are needed because they ensure that all the pharmaceutical goods are compliant with the regulations which govern the industry. Pharma regulatory affairs specialists guarantee that all the procedures and the intended goods meet specified basic safety and efficacy criteria inherent from the early application stages of new or generic medicines, through the licensing and marketing. In general, professionals act as the channel of communication between the drug manufacturing companies and the regulatory organizations such as the FDA and EU. They also need to be applicable in business, legal as well as the pharmaceutical industry so that they can well comprehend what regards regulations and specifications that have to be follow. As a result, this company's capacity to handle its RA (Regulatory Affairs) activities effectively is essential to optimum performance. If data reporting is insufficient, then a marketing application may not be assessed favorably on time. New medicine may have taken millions of euros, dollars, or pounds to develop, and there are financial explanations for any delay up to three months before its release on the market. Worse still, a product

recall may be inevitable due to situations where some data are not fully reported or a product is released to the market with wrong labeling information. These events could easily translate into several million units of sales lost and erode investor, physician and patient confidence [3].

1.3 Legislative Background of Drug Control

In its origin from the Dutch word "quacken," meaning "to boast," "quack" is the term Americans most frequently apply to the medical pretender. Prior to 1906, which the Pure Foods and Drugs Act, with its amendment that forbade it, was passed, charlatans could peddle poisonous impure and mislabeled patent medicines in the United States. Congress passed two major measures that extended FDA powers during the subsequent fifty years. Before the start of the Second World War, in 1938, it passed the Federal Food, Drug, and Cosmetic Act (FFDCA), which called for a prior determination of safety on drugs that were being shipped across state lines. Folks there after wait until 1962 for the Kefauver-Harris Drug Amendments to the FFDCA that standardize safety measure and apply that it is not only safe but also effective, after fatalities and birth malformations from the sedative thalidomide marketed in Europe. Congress modified the FFDCA many times, which set the present FDA direction of wanting the medication that American citizens take to be secure and operational. Knowledge is often referred to as currency of the 21st century and for registered nurses, this has been the case, always. In relation to regulators and regulatory authorities, regulatory plays the middleman role of a business or sponsor in its relations with outside world. Here, which earlier was mentioned as the problem, the regulatory department becomes the source of input and output of the information within the organisation. It is not possible to practice regulation and be successful in both external tangible standards, which are measurable (e.g., approval), and internal measures, which are tangible but confined to within the organization (e.g., reward and recognition) without acquiring information. This is because information is strong and regulation concerns it [4].

2. Regulatory Affairs Definition

Within a drug development organization, achieving a commercially significant goal requires a special blend of science and management. Covers every aspect of pharmaceuticals, starting with the earliest non-clinical research and continuing through development, routine manufacturing, and marketing. can have a major impact on both medication firms and patients.

3. The Role of Regulatory Affairs and Product Development

Compared to other channels, the drug items are more or less governed and regulated. Normally, regulatory organisations bear the task of maintenance and

supervision of these regulations. After this approval most of these organizations actually give guidelines on product development based on the existing IND (Investigational new Drug) guidelines. They also keep identifying the medicine's post-market attributes and the drug renewal time period.

Regulatory affairs for clinical trials: The regulatory affairs specialist is responsible for representing the company at the international level organizations. Among these duties is giving regular information on fresh data obtained during investigations, and assisting in the development of approval of new products for compliance with state and local regulations.

Regulatory affairs in Research &Development(R&D): In an effort to develop new contemporary products that conform to the new technology and regulations and to reduce TTM affairs personnel work with R and FR&D: It is believed that the new products will contribute to the company's revenues; though the marketing time hampers the original revenues the materials will have boosted the company's profits and total revenue over the material. The assessment of flexible modes of clinical trial, fast approval from the regulatory authority, and eliminating process hindrances will create new product facilitation and minimize mistakes and long time consumption [5].

Table 1: Regulatory Bodies in The World [6]

Country	Regulatory body
USA	Food and Drugs Administration (FDA)
UK	Medicines and Healthcare products Regulatory Agency (MHRA)
Australia	Therapeutics goods administration (TGA)
India	Central drug standard control organization (CDSCO)
Canada	Health Canada

4. India's Regulatory Approval and Submission Process Examining Novel Drugs in India

At the moment, before a medicine can be shipped or dispensed across state lines it has to be the subject of a marketing application approved in accordance with

federal statutes. A sponsor needs to seek an exemption for that legal provision because it is probable that the sponsor will be desirous of transporting the experimental medicine to Clinical Investigators in many states. Actually, the said exemption goes to the sponsor from the FDA. While in the initial stages of preclinical research of a novel medicine, the sponsor is primarily concerned with two questions: whether the product is sufficiently safe to use in readiness for commencement of human trials and if the compound shows sufficient pharmacological activity to merit commercialization. After a product is identified to better fit into the category of more research and development, the sponsor focuses on the information and data needed to demonstrate that using the product in small, initial phase trials is not going to endanger people's lives. If a new molecule has been assessed for its pharmacological activity and toxicity in animals, the sponsor of the medicine (often the manufacturer, or prospective marketer) wishes to assess its therapeutic or diagnostic efficacy in man. This is the stage where the FDA intervenes to develop the new drug. At that they become a new drug which is subjected to certain circumstances of the regulatory drug system and changes its legal standing under the Federal Food, Drug and Cosmetic Act. Three main sections of material must be included in the IND application: Animal Pharmacology and Toxicology Studies – Scientific information to permit the determinations of the product's relative safety for first human testing. All prior human drug use history is also given (usually international use). Manufacturing Information: Any and all information regarding the identification of the ingredients, producer, stability, and quality control measures with respect to the active pharmaceutical ingredient(s) of the assigned drug/substance and the finished product which contains(s) them. This data is then used to assess its capabilities to produce adequate batches of the medication for distribution in the business[7].

Documentation concerning C2: Investigation Procedures and Details concerning the application of first-phase trials are also directed and encapsulated in the proposed clinical studies. To decide if a professional is capable to perform the duties of clinical trial it is also useful to get information on qualifications of clinical investigators who are usually doctors and who oversee the application of the experimental compound. Finally, the proposals to adhere to the investigational new medication regulations, to obtain informed consent from the research subjects, as well as to have this study approved by the institutional review board (IRB).

As for the first step, the sponsor is not allowed to initiate a clinical trial before 30 calendar days have elapsed since the submission of the IND. During this

period the FDA has the opportunity to review the IND to determine whether research subjects are going to be exposed to unreasonable risk [9].

5. Clinical Protocols and Data for Researchers

The clinical research plan involves numerous steps to determine if people to be involved in the first phase trials would be put at undue risk. It is also important for deciding whether a professional is suitable for a clinical trial to know the background of clinical investigators, which are usually the medical workers responsible for managing the distribution of the test substance. Last of all, commitments to abide the new regulation for investigational drugs, to secure research subject's informed consent, and have the study reviewed by the board for institutional reviews (IRB). Further the sponsor cannot commence any clinical trials on the subjects until a period of thirty calendar days has elapsed right after the submission of IND [9].

The clinical studies were divided into two sub groups in 2006. While markets with capable and developed regulatory systems are in one category (Category A), the rest are in another (Category B), although clinical trials in all other markets can be conducted. Besides, A. Fast tracking is available to clinical studies of category A (approved in US, UK, Switzerland, Australia, Canada, Germany, South Africa, Japan, an EU) to be approved in India with in eight weeks. Category B clinical studies are reviewed and marketed more than Category C and take 16–18 weeks for approval. Application for conduct of clinical trials in India shall be made by the Indian investigational new drug sponsor with the efficacy, safety and toxicology data of the investigational new drug in terms of chemistry, manufacturing, control and animal study for the Drug Controller General of India (DCGI). Attached should also contain the date of informed consent documentation, investigator brochures, and protocol. Clinical trials can only be done after obtaining approvals from DCGI and Ethical committee and a photocopy of the application sent to them is mandatory to determine, adverse effects, the highest dose that is safe for humans, etc To determine… Phase I clinical trial is done on healthy human beings. Dose for Phase II is evaluated on 10-12 patients on each level to find therapeutic uses and optimal dose.

After the clinical trial stage is complete, the new drug registration (by completing form # 44 in conjunction with preclinical and clinical trial data) is used. Information, which is required in addition to safety and efficacy data, includes further particulars of the drug's marketing status in other countries. Companies must also provide information regarding the product monograph, labels, carton, sample, testing procedures and prescriptions.

A review of the application may take as long as twelve to eighteen months. Phase IV trials are considered when a product has been determined to be in the process of seeking confirmation for new uses, new populations, lasting consequences, etc. after obtaining the New Drug Application (NDA) which allows the firm to market and distribute the product.

Every country has a unique way of approving drugs. There are some countries where the overall responsibility for drug regulation covers things like; new drug approval, manufacturing licenses, and inspection of manufacturing plants. For instance, in the United States, all aspects of drug regulation are under the control of the Food and Drug Administration — commonly abbreviated as the FDA. However, in some of these nations, and particularly in India, not all functions are performed by a single board of regulation; rather, it is shared between the state and the central governments. Other areas that the two have big differences include the period taken to approve a CTD application, evaluate a marketing authorization application, pay the registration charge, register and the period provided under marketing exclusivity.

Some nations, like the USA, China, and others, have two review processes: namely, the first for normal review and the other for fast review. Other countries, for instance the India, only have one review process. Similarly to this, the dossier submitted for a drug clearance is presented in different formats. Some of the nations that require preparation of the dossier in the CTD format includes the USA, EU, and Japan while some of them do not; Including India.

6. Dossier (CTD)

In its simplest definition, A dossier is a file document that is turned in to seek approval for a new drug or medication product. It is delivered as a CTD. CTD is a standardized method or format for presenting data in the ICH regions of countries which stands for Common Technical Document. The type is obligatory in some countries but optional in others. The process of scrutinizing the medical product's dossier with a view to its marketing, or licensing, registration or approval, and so on, Is undoubtedly brought to a close with the issue of a document entitled marketing authorization. This procedure has been done under the guideline that sets the requirements on the application to be made to the competent authority; details on the assessment process which is in terms of safety, efficacy and quality; reasons for granting or refusing the application; and circumstances under which a marketing authorization that has been granted may be withdrawn, suspended or revoked. Since the CTD format is designed to provide guidelines for registration documentation format and organization, it pursues just this goal. Benefits Integration and submission of well-coordinated alternatives, more

straightforward composite assessment for applications, electronic submission assistance etc [10,11].

7. The Professional in Drug Regulatory Affairs

Due to the fact that pharma research and development is a complex and long process, it has to be handled professionally from start to end in order to meet all legal requirements and to gain a positive pure and simple assessment in the shortest possible time. This entails that drug regulatory affairs (DRA) professional is hugely relevant to each and every of this period beginning from the time where regulatory plans have to be drawn after new chemical entity has been discovered to the post marketing stage. The main responsibility of a DRA specialist is to clear medications for submission and ensure that the product is compliant with the FDA for both marketed and investigational drugs and guidances, polices, and regulations. Under this mechanism, the DRA practitioner should be scientifically qualified including B. Sc., M.Sc., Ph.D., M.D., B. Pharm, M. Pharm or Pharm. D., and have systematically and scientifically arrived at an understanding of Indian and international laws. It is gradually broadening to become standardized around the international level, partly because many ICH guidelines are now in effect and because different health authorities around the world are increasingly recognising each other. For this reason, it is nearly impossible for DRA professionals to easily monitor policy changes and understand the nature of the impact on the approval process [12-13].

8. Regulatory affairs' role

The RA section within the pharmaceutical business is responsible for seeking approval for new pharmaceutical treatments or medication and also to manage approval maintenance throughout the entire targeted period (14). Both from a financial and a science perspective, regulatory affairs specialists greatly enhance a development initiative and the business, by bringing technology and strategic guidance to all the production, quality control, research and development, and other areas well before a product is midstream [15]. Furthermore, as a part of their responsibility, they are supposed to make available truthful descriptions of the safety features, effectiveness, and quality of the products being marketed to physicians and various other healthcare givers. It also participates in the formulation of marketing strategies for drugs under development. Any style of packaging and marketing for a product or drug has to be reviewed by regulatory affairs before going on the market [16]. Roles of regulatory affairs in different departments are presented in the figure 1 below.

As a part of their responsibilities, they are to give all data connected to the safety, effects, and quality of the

products to medical practitioners and other healthcare providers. This committee also specializes in marketing strategies in drug development. In a similar manner, a product or drug packaging and marketing contain regulatory affairs into consideration before being used in commerce [17].

Figure 1: Contributions of Regulatory affairs in different departments

Conclusion

Only a few in the regulatory affairs profession will disagree with the observation that the New Approach to regulation will be the method of choice for the authorisation of all healthcare goods in the future since it is the only approach that allows new medical solutions to reach the market on time and in satisfactory terms of safety and efficacy. The area of Regulatory Affairs as a organizational division is an actively developing and dynamically growing subdivision in the modern conditions determined by the presence of technologies. Businesses also partly outsource or out task regulatory affairs to other service providers due to variations of resources needed for compliance with regulations. Indeed, in today's environment the speed at which a product and therefore the company get to the market place largely determines the fate of the product. So it is imperative that the company effectively coordinate its Regulatory Affairs activities to avoid affecting its financial performance.

Acknowledgment

It's great pleasure for me to acknowledge all those who helped me and supported me.I would like to express my sincere gratitude to our principal ***Dr. Ashish Jain*** and to the management for their constant encouragement and providing all necessary facilities. My deepest thanks to my guide ***Mr. Mukesh S Patil*** for guiding and making necessary corrections as and when needed. I express my sincere gratitude to PG Incharge ***Dr. Bhushan Rane*** for his kind cooperation and guidance.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Authorship contribution statement

Mukesh Patil: Supervision, Validation, Methodology, Investigation, Writing – original draft, Nanduri **Sri Sesha Sai Swaroop:** Conceptualization, Administration. **Ashish S Jain**: Funding, Data Curation.

References

1. Monappa R. Sutar, Deepali R. Gawhane, C.R.Tenpe, ―Study of Drug Regulatory Approval Process and Comparative Requirement of Common Technical Documents (CTD) in Europe, USA and India in Coordination with Drug Developmental Process‖ International Journal . Pharmacutical Science and Research, 2013; 20: 68-79.
2. E.Gopinath, R.S. Bhadauria, Jodan Gunjan, zaidi Insha, ―Pharmaceutical regulatory affairs – review‖, International Journal of Advanced Research in Pharmaceutical and Biosciences, 2012; 2(2): 292-301.
3. D.K. Sanghi, Rakesh Tiwle, ―Role of regulatory affairs in a pharmaceutical industry‖, IJPRR, 2014; 4: 127-131.
4. G. Sushma, Subal debnath, Santhosh Kumar C, Atul N Chandu, ―Quality and regulatory affairs of herbal drugs: A world-wide Review‖, Indo American Journal of Pharmaceutical Research, 2011; 1: 389-396.
5. D. Sreedhar, G.Subramanian, M. Sreenivasa Reddy and N.Udupa, ―need for the introduction of regulatory affairs in the pharmacy curriculum‖, Health Administrator, XIX(1): 51-52.
6. Naishi Kirtikumar, Dilip Maheshwari, ―Documentation Requirements for Generic Drug Application to be marketed in India- A Review‖, JPSBR., 2014; 4(4): 237-242.
7. Sumit Kumar, Rishabh Panwar, Upendra Singh, ―Regulatory affairs in the pharmacy

curriculum‖, International Journal of Research and Development in Pharmacy and Life Sciences, October - November, 2013; 2: 690-698.

8. Training Needs in Regulatory Science for the Biopharmaceutical Industry, Nature Jobs Biotechnology, 2001; 19(12): 1187-1188.
9. Careers in Regulatory Affairs from Practitioner to professional, Nature Jobs Biotechnology, 2002; 20(4): 409-410.
10. Sachin C Itkar, Dr. Ns Vyawahare, ―Drug Regulatory Affairs‖, Third edition (2015).
11. ―Need For the Introduction of Regulatory Affairs in the Pharmacy Curriculum‖ Health Administrator, XIX(1): 51-52.
12. G.Sai Hanuja, B.Sai Kumari, M.V.Nagabhushanam, D.Nagarjuna Reddy, Brahmaiah Bonthagarala, Regulatory Requirements for Registration of Generic Drugs in ―BRICS‖ Countries, International Journal of Pharmaceutical Science and Health Care, ISSN 2249 – 5738, November-December, 2016; 6; 20-40.
13. B.Sai Kumari, G.Sai Hanuja, M.V. Nagabhushanam, D.Nagarjuna Reddy, Brahmaiah Bonthagarala, Current Regulatory Requirements for Registration of Medicines, Compilation and Submission of Dossier in Australian Therapeutic goods Administration, International Journal of Advanced Scientific and Technical Research, ISSN 2249-9954, November December, 2016; 6;144-157.
14. Chandra, A. and Kumar, B., 2016. A comparitive study of the drug approval process in USA, INDIA, JAPAN AND EUROPE. World journal of pharmaceutical Research, 6;pp.311-322
15. Chakraborty, K. and Yadav, K., 2018. Drug approval process in US, EUROPE and India and its regulatory requirements: A Review. International journal of Drug regulatory Affairs, 6; pp.31-39.
16. Raj, R., Pattanaik, P. and Roy, H., 2015. The Dynamics of Global pharma Regulatory Affairs system. Indo American Journal of pharmacy, 1; pp